We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMTFB
RNS Number : 7265T
Motif Bio PLC
09 January 2017
Motif Bio plc
("Motif Bio" or the "Company")
Issue of Equity and Total Voting Rights
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics announces that it has issued 143,700 new ordinary shares in the Company ("Ordinary Shares") as a result of the exercise of options.
Application has been made for the 143,700 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 13 January 2017. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 195,885,228 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.
For further information please contact:
Motif Bio plc info@motifbio.com Graham Lumsden (Chief Executive Officer) Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Giles Balleny Dominic Wilson +44 (0)20 3829 5000 Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking) +44 (0)20 3861 6625 Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com PR & IR) Mob: +44 (0)7980 541 893 Paul McManus Mob: +44 (0)7900 608 002 Mike Wort MC Services AG (EUROPEAN IR) Raimund Gabriel +49 (0)89 210 2280
About Motif Bio plc www.motifbio.com
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUGUMPGUPMGMB
(END) Dow Jones Newswires
January 09, 2017 12:28 ET (17:28 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions